Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients treated with cetuximab and radiotherapy on TROG 12.01 and De-ESCALaTE randomized trials.

Danny Rischin,Hisham Mehanna,Richard J. Young,Mathias Bressel,Janet A. Dunn,June Corry,T. Fulton-Lieuw,Gulnaz Iqbal,Lizbeth Kenny,Sandro V. Porceddu,Chris Wratten,Max Robinson,Benjamin Solomon

Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients treated with cetuximab and radiotherapy on TROG 12.01 and De-ESCALaTE randomized trials.

2021

Danny Rischin
Hisham Mehanna
Richard J. Young
Mathias Bressel
Janet A. Dunn
June Corry
T. Fulton-Lieuw
Gulnaz Iqbal
Lizbeth Kenny
Sandro V. Porceddu
Chris Wratten
Max Robinson
Benjamin Solomon

109Background: Trials in human papilloma virus associated oropharyngeal squamous cell carcinoma (HPVOPSCC), substituting cetuximab (CETUX) for cisplatin (CIS) with radiotherapy (RT), resulted in de...

Keywords:

Immune system
Internal medicine
Cell
Cancer
Oncology
Medicine
Cetuximab
Randomized controlled trial
Radiation therapy
poor prognosis
Cisplatin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations